AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 173 min read$BMY

Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued After Phase 2 Trial News

Bristol-Myers Squibb (BMY) stock has risen 44.4% over the past year. Positive Phase 2 data for arlocabtagene autoleucel in multiple myeloma may influence future cash flows. The company's free cash flow is around $11.5 billion, with projections ranging from $10 billion to $13 billion annually. A discounted cash flow model suggests the stock may be undervalued by 46% at its current price of $63.60, according to Simply Wall St.

Original reporting
simplywall.st
Published Sep 17, 2026, 12:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued After Phase 2 Trial News — source image
Source · simplywall.st
Decision brief

The 30-second read

$BMYBullishMed
01

Why it matters

The disclosed trial data could lead to a re‑rating of BMY's growth outlook and affect its price relative to intrinsic value estimates.

02

Market read

New clinical data may drive investor re‑assessment of BMY's valuation and influence biotech sector sentiment.

03

What to watch

Potential regulatory hurdles and competition from other CAR‑T therapies could temper upside.

Relevance 8/10Novelty 8/10Timing: recent Phase 2 data release

Background

The article evaluates Bristol Myers Squibb's valuation in light of recent Phase 2 trial data and cash flow metrics.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Positive Phase 2 data for arlocabtagene autoleucel in relapsed and refractory multiple myeloma was disclosed, potentially affecting future cash flows and valuation.

Expected impact

Potential upside if data leads to further development and eventual approval.

Evidence & confidence

Phase 2 data is material for a biotech; investors may reprice the stock based on improved growth prospects.

Market effects

Sector

May lift sentiment for the broader oncology biotech sector.

Regional

Limited to U.S. and global biotech investors.

Global

Relevant to global pharma investors tracking oncology pipelines.

Counterpoint

What could challenge this read

Skeptics may argue the data is early-stage and not sufficient to justify a valuation jump.

Key entities

  • company
    Bristol Myers Squibb

    Pharmaceutical company reporting Phase 2 trial results.

Read at source← All news

Related articles

SEP 17
$BMYMedAI 9/10

Bristol Myers Squibb reports Sotyktu two-year trial results

Bristol Myers Squibb (BMY) reported two-year Phase 3 trial results for Sotyktu, showing sustained efficacy and no new safety signals in adults with psoriatic arthritis. ACR20/50/70 response rates were 76.2%, 52.6%, and 34.6% at Week 104 for continuous treatment. The company plans to present full results at upcoming medical conferences.

grafa.com2 min
SEP 17
$BMYMedAI 9/10

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Bristol Myers Squibb (BMY) reported two-year data from the POETYK PsA-2 study, showing durable efficacy and consistent safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. ACR20/50/70 response rates at Week 104 were 76.2%/52.6%/34.6% (observed) and 65.3%/44.9%/29.4% (NRI) for continuous Sotyktu treatment. Safety profile remained consistent with no new signals. Results were presented at the Congress of Clinical Rheumatology - West.

biospace.com2 min
SEP 17
$BMYMedAI 8/10

BMY Looks 12.4% Overvalued on GF Value™ as Dividend Sustainabili

Bristol-Myers Squibb (BMY) reported positive Phase 3 trial results for Sotyktu in treating psoriatic arthritis. The company offers a 3.95% dividend yield with a 39% payout ratio and a 4.4% 3-year dividend growth rate. BMY's GF Score is 71, indicating strong profitability but modest growth. Insiders and gurus have shown net selling. The stock trades 12.4% above its GF Value of $56.60.

gurufocus.com2 min
SEP 17
$BMYMedAI 8/10

Bristol Myers Squibb reports two-year Sotyktu psoriatic arthritis data

Bristol Myers Squibb (BMY) presented two-year data from the POETYK PsA-2 study, showing continued efficacy and safety of Sotyktu in treating psoriatic arthritis. Key response rates were reported for patients on continuous Sotyktu and those who switched from placebo. The study included 729 patients, with adverse events occurring in 86.6% of participants. Sotyktu was approved earlier this year for this indication.

investing.com2 min